7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $140M | -$80M | 0.0% | -274.6% | -$360M | — | $295M |
| 2024 | $64M | -$377M | 0.0% | -654.3% | -$356M | — | $282M |
| 2023 | $378M | -$133M | 0.0% | -46.7% | -$183M | — | $436M |
| 2022 | $61M | -$289M | 0.0% | -555.6% | -$26M | — | $233M |
| 2021 | $52M | -$371M | 0.0% | -757.0% | -$113M | — | $560M |
| 2020 | $24000 | -$195M | 0.0% | -553166.7% | -$112M | — | $162M |
| 2019 | $18000 | -$78M | 0.0% | -417522.2% | -$85M | — | $37M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $32M | -$94M | 0.0% | -337.8% | -$131M | $100M | $288M |
| Dec '25 | $114M | $244M | 0.0% | -15.3% | -$87M | — | $295M |
| Sep '25 | $10M | -$113M | 0.0% | -1307.6% | -$86M | — | $268M |
| Jun '25 | $8M | -$102M | 0.0% | -1419.2% | -$80M | — | $282M |
| Mar '25 | $7M | -$108M | 0.0% | -1596.9% | -$107M | — | $528M |
| Dec '24 | $30M | -$90M | 0.0% | -332.7% | -$79M | — | $282M |
| Sep '24 | $14M | -$97M | 0.0% | -746.4% | -$90M | — | $230M |
| Jun '24 | $12M | -$91M | 0.0% | -891.1% | -$85M | — | $293M |
| Mar '24 | $7M | -$99M | 0.0% | -1405.3% | -$102M | — | $288M |
| Dec '23 | $316M | $143M | 0.0% | 42.0% | $131M | — | $436M |
| Sep '23 | $17M | -$96M | 0.0% | -629.7% | -$98M | — | $169M |
| Jun '23 | $20M | -$83M | 0.0% | -507.8% | -$101M | — | $226M |
| Mar '23 | $24M | -$96M | 0.0% | -408.7% | -$116M | — | $250M |
| Dec '22 | $20M | -$38M | 0.0% | -444.1% | -$77M | — | $233M |
| Sep '22 | $16M | -$110M | 0.0% | -577.9% | -$86M | — | $157M |
| Jun '22 | $17M | -$72M | 0.0% | -492.2% | -$74M | — | $266M |
| Mar '22 | $8M | -$69M | 0.0% | -904.0% | $211M | — | $297M |
| Dec '21 | $51M | -$65M | 0.0% | -124.3% | -$12M | — | $560M |
| Sep '21 | $763000 | -$28M | 0.0% | -9126.3% | -$3M | — | $612M |
| Jun '21 | $6000 | -$76M | 0.0% | -982900.0% | -$49M | — | $212M |
How the market has priced BEAM against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Beam Therapeutics Inc.'s revenue has grown 466.3% per year. These are computed facts, not advice.
As of FY2025, Beam Therapeutics Inc. reported — of total debt against $295M of cash.
In FY2025, gross margin was —, operating margin -274.6%, and net margin -57.2%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.